• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Israel·Healthcare·EPIT.TA
Share

Epitomee Medical Ltd Stocks

ILA 336.3Last Updated 30.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

ILA 324644.34772

ILA 336.3
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.11.2026 17:42

One of the boldest bets: Marvell will acquire optics developer Lumentum for $115 billion

02.11.2026 17:30

Shares of biotech company Inovio soared 240% following the drug's approval. Is there still upside potential?

02.11.2026 17:08

"Hope for a Breakthrough in the Iran Stalemate": Oil Prices Plunge 4%

02.11.2026 16:18

Morning in New York: The High-Tech Sector Cools Off Ahead of the Election

02.11.2026 16:04

"I know he's an idiot": Ryanair CEO assesses the business benefits of his feud with Musk

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026